Literature DB >> 15342273

Activation of brain stem nuclei by improgan, a non-opioid analgesic.

J W Nalwalk1, K Svokos, O Taraschenko, R Leurs, H Timmerman, L B Hough.   

Abstract

Improgan is a compound developed from histamine antagonists which shows the pre-clinical profile of a highly effective, non-opioid analgesic when administered into the rodent CNS. Pharmacological studies suggest that improgan activates descending pain-relieving circuits, but the brain and spinal sites of action of this drug have not been previously studied. Presently, the effects of intracerebral and intrathecal microinjections of improgan were evaluated on thermal nociceptive responses in rats. Improgan produced large, dose- and time-related reductions in nociceptive responses following administration into the ventrolateral periaqueductal gray (PAG), the dorsal PAG, and the rostral ventromedial medulla (RVM). The drug had no measurable effects after injections into the caudate nucleus, basolateral amygdala, hippocampus, ventromedial hypothalamus, superior colliculi, ventrolateral medulla, or the spinal subarachnoid space. Inactivation of the RVM by muscimol microinjections completely attenuated antincociceptive responses produced by intraventricular improgan. These findings, taken with earlier results, show that, like opioids and cannabinoids, improgan acts in the PAG and RVM to activate descending analgesic systems. Unlike these other analgesics, improgan does not act in the spinal cord or in CNS areas outside of the brain stem.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15342273     DOI: 10.1016/j.brainres.2004.06.066

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  11 in total

1.  Physiological basis for inhibition of morphine and improgan antinociception by CC12, a P450 epoxygenase inhibitor.

Authors:  Mary M Heinricher; Jennifer J Maire; Delaina Lee; Julia W Nalwalk; Lindsay B Hough
Journal:  J Neurophysiol       Date:  2010-10-06       Impact factor: 2.714

2.  Efficacy of improgan, a non-opioid analgesic, in neuropathic pain.

Authors:  Phillip J Albrecht; Julia W Nalwalk; Lindsay B Hough
Journal:  Brain Res       Date:  2011-10-08       Impact factor: 3.252

3.  Neural basis for improgan antinociception.

Authors:  M M Heinricher; M E Martenson; J W Nalwalk; L B Hough
Journal:  Neuroscience       Date:  2010-05-24       Impact factor: 3.590

4.  Antinociceptive activity of CC44, a biotinylated improgan congener.

Authors:  Paul Hoerbelt; Julia W Nalwalk; James G Phillips; Mark P Wentland; Zhixing Shan; Lindsay B Hough
Journal:  Eur J Pharmacol       Date:  2013-07-05       Impact factor: 4.432

5.  CC12, a P450/epoxygenase inhibitor, acts in the rat rostral, ventromedial medulla to attenuate morphine antinociception.

Authors:  Jennie L Conroy; Julia W Nalwalk; James G Phillips; Lindsay B Hough
Journal:  Brain Res       Date:  2013-01-05       Impact factor: 3.252

6.  CC12, a high-affinity ligand for [3H]cimetidine binding, is an improgan antagonist.

Authors:  Lindsay B Hough; Julia W Nalwalk; James G Phillips; Brian Kern; Zhixing Shan; Mark P Wentland; Iwan J P de Esch; Elwin Janssen; Travis Barr; Rebecca Stadel
Journal:  Neuropharmacology       Date:  2007-01-20       Impact factor: 5.250

7.  Antinociceptive activity of furan-containing congeners of improgan and ranitidine.

Authors:  L B Hough; W M P B Menge; A C van de Stolpe; J W Nalwalk; R Leurs; I J P de Esch
Journal:  Bioorg Med Chem Lett       Date:  2007-08-19       Impact factor: 2.823

Review 8.  Descending control of nociception: Specificity, recruitment and plasticity.

Authors:  M M Heinricher; I Tavares; J L Leith; B M Lumb
Journal:  Brain Res Rev       Date:  2008-12-25

9.  Non-opioid antinociception produced by brain stem injections of improgan: significance of local, but not cross-regional, cannabinoid mechanisms.

Authors:  Lindsay B Hough; Konstantina Svokos; Julia W Nalwalk
Journal:  Brain Res       Date:  2008-10-21       Impact factor: 3.252

10.  Significance of cannabinoid CB1 receptors in improgan antinociception.

Authors:  Neal C Gehani; Julia W Nalwalk; Raj K Razdan; Billy R Martin; Xufung Sun; Mark Wentland; Mary E Abood; Lindsay B Hough
Journal:  J Pain       Date:  2007-07-23       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.